Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Vet J ; 200(1): 162-9, 2014 Apr.
Article En | MEDLINE | ID: mdl-24675370

The aim of this study was to investigate the efficacy of intra-articular (IA) botulinum toxin A (IA BoNT A) for the treatment of osteoarthritic joint pain in dogs. The study was a placebo-controlled, randomized, double-blinded clinical trial with parallel group design and 12-week follow-up. Thirty-six dogs with chronic lameness due to stifle, hip or elbow osteoarthritis were randomized to receive an IA injection of 30IU of BoNT A or placebo. The main outcome variables were vertical impulse (VI) and peak vertical force (PVF) measured with a force platform, and Helsinki chronic pain index (HCPI). Subjective pain score and the need for rescue analgesics were secondary variables. The response to treatment was assessed as the change from baseline to each examination week. The variables were analyzed by ANOVA with repeated measurements and results were considered statistically significant if P ⩽ 0.05. The improvement from baseline to 12 weeks after baseline was statistically significant in VI, PVF and HCPI in the treatment group (P=0.001, P=0.054 and P=0.053, respectively). Additionally, there were statistically significant improvements in VI in the treatment group at 2, 4 and 8 weeks after baseline (P=0.037, P=0.016 and P=0.016, respectively). The difference between groups in improvement in VI was statistically significant at 12weeks after baseline (P=0.005). There was no significant change in the subjective pain score or in the requirement for rescue analgesics in either group. No major adverse events thought to be related to trial protocol were detected. These results suggest that IA BoNT A has some efficacy in reducing osteoarthritic pain in dogs.


Analgesics/therapeutic use , Arthralgia/veterinary , Botulinum Toxins, Type A/therapeutic use , Dog Diseases/drug therapy , Osteoarthritis/veterinary , Pain Management/veterinary , Animals , Arthralgia/drug therapy , Arthralgia/etiology , Dog Diseases/etiology , Dogs , Double-Blind Method , Female , Injections, Intra-Articular/veterinary , Male , Osteoarthritis/drug therapy , Osteoarthritis/etiology , Treatment Outcome
2.
Eur J Clin Nutr ; 67(9): 1000-2, 2013 Sep.
Article En | MEDLINE | ID: mdl-23900242

We report associations of saturated fat (SF) intake with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), concurrent IFG+IGT and type 2 diabetes (T2DM) at different levels of cardiorespiratory fitness and body mass index (BMI). In a population-based sample (n=1261, age 58-78 years), oral glucose tolerance, 4-day food intake and maximal oxygen uptake were measured. High intake of SF (>11.4 E%) was associated with elevated risk for IFG (4.36; 1.93-9.88), concurrent IFG+IGT (6.03; 1.25-29.20) and T2DM (4.77; 1.93-11.82) in the category of high BMI (>26.5) and high fitness, whereas there was no significantly elevated risk in individuals reporting low intake of SF. Concurrent high BMI and low fitness were associated with elevated risks. In general, SF intake and fitness did not differentiate the risk of abnormal glucose metabolism among subjects with low BMI. Limited intake of SF may protect from diabetogenic effects of adiposity, but only in individuals with high level of fitness.


Dietary Fats/administration & dosage , Fatty Acids/administration & dosage , Obesity/physiopathology , Physical Fitness/physiology , Aged , Blood Glucose/metabolism , Body Mass Index , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Energy Intake , Energy Metabolism , Fasting/blood , Glucose Intolerance , Glucose Tolerance Test , Humans , Middle Aged , Obesity/complications , Retrospective Studies
3.
Eur J Clin Nutr ; 66(7): 819-24, 2012 Jul.
Article En | MEDLINE | ID: mdl-22415336

BACKGROUND/OBJECTIVES: Impaired fasting plasma glucose (IFG) and impaired glucose tolerance (IGT) predict development of type 2 diabetes (T2D), but display different pathophysiology for T2D. We studied the association of selected food items and nutrients with IFG, IGT and combined IFG and IGT (IFG+IGT), independent of cardiorespiratory fitness (VO(2max)). SUBJECTS/METHODS: In a population-based sample of 1261 individuals, aged 58-78 years, we identified 126 subjects with IFG, 97 with IGT and 49 with simultaneous IFG and IGT by an oral glucose tolerance test. Dietary intake was assessed by 4-day food records. Cardiorespiratory fitness was assessed by defining maximal oxygen uptake (VO(2max)) from respiratory gas analysis during a maximal symptom-limited exercise stress test on a bicycle ergometer. RESULTS: Increased intake of saturated fat was associated with higher odds for IFG (OR 1.07; 1.01-1.14) after adjustment for age, gender, VO(2max) and energy misreporting variable. Consumption of additional whole-grain bread (50 g/1000 kcal) and intake of dietary fiber (g/1000 kcal) were inversely associated with IGT (OR 0.61; 0.41-0.92, OR 0.91; CI 0.85-0.97, respectively). CONCLUSION: Dietary fiber and sources of cereal fiber are negatively associated with IGT, and saturated fat intake is positively associated with IFG, but not with IGT. The present data give practical dietary means at the population level for the elimination of prediabetic conditions.


Diet/adverse effects , Dietary Fats/adverse effects , Energy Intake , Fatty Acids/adverse effects , Glucose Intolerance/prevention & control , Hyperglycemia/prevention & control , Prediabetic State/diet therapy , Aged , Bicycling/physiology , Blood Glucose/metabolism , Bread , Cardiovascular System , Diet Records , Dietary Fiber/pharmacology , Dietary Fiber/therapeutic use , Edible Grain , Exercise Test , Fasting , Female , Glucose Intolerance/blood , Glucose Intolerance/etiology , Glucose Tolerance Test , Humans , Hyperglycemia/blood , Hyperglycemia/etiology , Male , Middle Aged , Odds Ratio , Oxygen Consumption , Prediabetic State/blood , Respiration , Respiratory System
...